AVTX insider trading
HealthcareAvalo Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Company website: www.avalotx.com
AVTX insider activity at a glance
FilingIQ tracks 173 insider transactions for AVTX in filings since Sep 17, 2021. The most recent transaction is dated Sep 16, 2026.
Across the full history, 68 open-market purchases
and 45 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AVTX insider trades is 56.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AVTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AVTX?
- FilingIQ tracks 173 Form 4 insider transactions for AVTX (Avalo Therapeutics, Inc.), covering filings from Sep 17, 2021 onwards. 19 of those are dated within the last 90 days.
- Are AVTX insiders net buyers or net sellers?
- Across the full Form 4 history for AVTX, 68 transactions (39%) were open-market purchases and 45 (26%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AVTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AVTX in?
- Avalo Therapeutics, Inc. (AVTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $266.21M.
Methodology & sources
Every AVTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.